TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: NGLY1 Deficiency: A Prospective Natural History Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Parent(s)/legal representative and/or participant must be willing and able to give informed consent/assent for participation in the study~* Males or females of any age~* Suspected or confirmed diagnosis of NGLY1 deficiency with genetic variants in both NGLY1 alleles and consistent clinical characteristics~* Participant and caregiver must be willing to provide clinical data, participate in standardized assessments, and provide biological samples (if living in the United States)~* Willingness to travel to Palo Alto, CA is favored, but not required~Exclusion Criteria:~* The presence of a second, confirmed disorder, genetic or otherwise, affecting neurodevelopment or with other overlapping symptoms of NGLY1 deficiency

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Pediatric Patients for Pain Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children with spasticity requiring BTI~* Children ages 5 - 18~* Children who have contraindications for sedation for BTI~* Children with intact vision who can attend VR intervention~Exclusion Criteria:~* Children who have uncontrolled seizures \> than 4 per year~* Children who are not attentive to VR secondary to poor concentration, poor cognition to external stimuli~* Children on different treatments for spasticity such as baclofen pump, phenol block. For patients who receive phenol block, phenol block will be held during the visits with VR intervention to avoid confounding results~* Children with poor bleeding control~* Children who request general anesthesia/IV sedation.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Google Cardboard VRA (Type: ACTIVE_COMPARATOR): This group of subjects will receive VRA intervention using Google Cardboard Virtual reality head- mounted display powered by a iPod touch.
- Oculus Rift VRA (Type: ACTIVE_COMPARATOR): This group of subjects will receive VRA with Oculus Rift
- Control (Type: NO_INTERVENTION): This group of subjects will receive no intervention beyond standard sedation, anesthetic, and/or restraint-this group will serve as the control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with stage I-IV non-small cell lung cancer(with no restriction of age, gender, or smoking history)~* Patients in the group will be allowed to collect whole blood and tissue samples at specific time points~* Eastern Cooperative Oncology Group Performance Status of 0-1 within 28 days prior to registration~* No previous systemic anti-tumor therapy~* Signed informed consent~Exclusion Criteria:~* Active or history of autoimmune disease or immune deficiency~* Patients with serious mental disease~* Prior allogeneic stem cell or solid organ transplantation~* Pregnant or lactating women~* Patients who cannot obtain tumor tissue samples and / or whole blood~* Patients with history of blood transfusion within half a year~* Patients with any other malignancy diagnosed within 5 years~* Received systemic anti-tumor therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of malignancy~  * Planning to receive therapy with an inhibitor of the EGFR pathway (either on or off a clinical trial and may be monotherapy or combined with other therapies)~* Normal serum magnesium level~Exclusion Criteria:~* Glomerular filtration rate ≥ 60 mL/min~* No severe underlying renal dysfunction~* Normal serum potassium and calcium level~* No history of primary or secondary hyperparathyroidism~PRIOR CONCURRENT THERAPY:~* No prior EGFR pathway inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naïve~* Age 18 and older~* Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive \> 6 months~* Detectable serum quantitative HCV-RNA (Cobas Taqman v2.0, Roche Diagnostics) with HCV RNA \> 800,000 IU/mL~* HCV genotype 1 (Inno-LiPA, Innogenetics)~* A liver biopsy consistent with the diagnosis of chronic hepatitis C~Exclusion Criteria:~* Anemia (hemoglobin \< 13 gram per deciliter for men and \< 12 gram per deciliter for women)~* Neutropenia (neutrophil count \<1,500 per cubic milliliter)~* Thrombocytopenia (platelet \<90,000 per cubic milliliter)~* Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Chronic alcohol abuse (daily consumption \> 20 gram per day)~* Decompensated liver disease (Child-Pugh class B or C)~* Serum creatinine level more than 1.5 times the upper limit of normal~* Autoimmune liver disease~* Neoplastic disease~* An organ transplant~* Immunosuppressive therapy~* Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases, psychiatric diseases, neurological diseases, diabetes mellitus~* Evidence of drug abuse~* Unwilling to have contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DFPP and Peg-IFN + RBV (Type: EXPERIMENTAL): Double filtration plasmapheresis (Day 1, Day 2, Day 4, Day 8, and Day 9 from the onset of treatment; overall 5 session, each session for 4 hours) and weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1 to week 48; body weight \< 75 kg, 1,000 mg/day and body weight \>= 75 kg, 1,200 mg/day)
- Peg-IFN + RBV (Type: ACTIVE_COMPARATOR): Weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1-48; body weight \< 75 kg, 1,000 mg/day and body weight \>=75 kg, 1,200 mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven adenocarcinoma of the prostate~* Deemed a surgical candidate for a bilateral nerve bundle preservation~* Potent~* Continent of urine~* Surgical candidate for both open and robotic nerve-sparing radical prostatectomy~* Age \>18~Exclusion Criteria:~* Previous treatment of prostate cancer (radiation, hormones, etc.)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Radical Prostatectomy (Type: ACTIVE_COMPARATOR): None
- Robotic radical prostatectomy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman ≥ 18 years old~* Brugada syndrome diagnosed with a type 1 ECG either spontaneous or drug-induced~* Electrophysiological study indicated for arrhythmic risk stratification purpose~* Inducibility of a sustained ventricular tachycardia (\> 30 seconds) or ventricular fibrillation requiring defibrillation~* Physical medical examination~* Signed written informed consent~Exclusion Criteria:~* Personal or familial history of epilepsy~* Pregnancy~* Body weight \> 100 kg~* the need of \>1 counter shock for defibrillation~* Alcohol or cocaine consumption during the protocol~* Class I (with the exception of local anaesthesia by lidocaine), II, III and IV antiarrhythmic drugs, antidepressant drugs, ATP dependent potassium channel activators, sultopride not stopped for \> 7 halve-lives~* No medical insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 3,4-Di-amino-Pyridine : a single 20 mg dosing
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who received a dual cord blood transplant are eligible and must have achieved donor cord blood chimerism of \> 75% in both T-cell and myeloid lineages~* At the time of thymus transplantation, subjects cannot have active grade II-IV acute graft versus host disease.~* At the time of thymus transplantation, the subject must have an absolute neutrophil count of \> 500/ul and a platelet count of 50,000/ul (even if achieved via transfusion).~* At the time of thymus transplantation, the subject must have \< or equal to 50 circulating CD 34+ cells/ul (as measured within 3 weeks of transplant date).~* At the time of thymus transplantation, subjects cannot be on greater than 2 mg/kg/day methylprednisolone or its equivalent of steroids.~* At the time of thymus transplantation, PT and PTT must be less that 1.5 times the ULN or must be correctable to this level.~* At the time of thymus transplantation, subjects cannot require oxygen or have pulmonary disease that would be thought to make general anesthesia a high risk.~* Subjects must be between the ages of 18 and 60 years of age.~Exclusion Criteria:~* Subjects cannot have bone marrow flow cytometry demonstrating residual leukemia~* Subjects cannot have insufficient subcutaneous tissue and muscle mass to be able to accept and heal a thymus transplant, as assessed by a surgeon.~* Prior to thymus transplantation, subjects cannot have evidence of active disease with HHV6, West Nile Virus, EBV, and CMV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Thymic tissue from third party donor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age 28-32 completed weeks, inclusive~* Placement of arterial line~* Successful initiation of nCPAP~* Informed Consent~Exclusion Criteria:~* Heart rate that cannot be stabilized \>100 bpm within 5 minutes of birth~* Five (5) minute Apgar score ≤ 3~* Major congenital malformation(s) diagnosed antenatally or noted immediately after birth~* Other disease(s) or conditions potentially interfering with cardiopulmonary function~* Mother with prolonged rupture of membranes \> 2 weeks~* Known or suspected chromosomal abnormality~* Need for chest compressions or administration of epinephrine, bicarbonate, or fluid boluses in the delivery room~* Need for mechanical ventilation within 30 minutes of birth

- Gender: ALL
- Minimum Age: 15 Minutes
- Maximum Age: 30 Minutes
- Healthy Volunteers: f

Study Arms:
- Regimen 1 (Type: EXPERIMENTAL): None
- Regimen 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tamsulosin as Adjuvant Treatment Prior to Endoscopic Ureterolithotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with urolithiasis undergoing to endoscopic ureterolithotomy~Exclusion Criteria:~* Patients with previous ureteral catheter~  * Patients with allergy to tamsulosin~ * Patients currently in treatment with tamsulosin for other disease different than ureterolithiasis~ * Multiple ureterolithiasis~ * Patients with impairment of their mental status~    * Patients with open surgeries in the affected ureter or urinary diversion~   * Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tamsulosin hydrochloride (Type: EXPERIMENTAL): Tamsulosin hydrochloride 0,4 mg tablets by mouth per day for 5 days before ureteroscopy
- Placebo oral tablet (Type: PLACEBO_COMPARATOR): Placebo oral tablets by mouth per day for 5 days before ureteroscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Dextromethorphan in Rett Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. those who have classic or atypical RTT with a proven mutation in the MeCP2 gene;~2. those with documented EEG evidence of spike activity who may or may not have clinical seizures;~3. subjects must be between 2years -14.99 years of age.~Exclusion Criteria:~1. those without an established mutation in the MeCP2 gene;~2. those who do not have EEG evidence of spike activity;~3. those with mutations in the MeCP2 gene but who have had brain resection or surgical intervention; for example, tumor, hydrocephalus, severe head trauma; or, an associated severe medical illnesses such as vasculopathies, malignancies, diabetes, thyroid dysfunction, etc;~4. those on medications that could interact with DM, e.g. monoamine oxidase (MAO) inhibitors, selective serotonin reuptake inhibitor (SSRI), sibutramine etc. to avoid a serotonin syndrome; quinidine and drugs metabolized by the Cytochrome P450 (CYP450) isoform cytochrome P450 2D6 (CYP2D6) (e.g. amiodarone, haloperidol, propafenone, thioridazine);~5. those proven to be intermediate or slow metabolizers of DM;~6. those with reported adverse reactions to DM;~7. those whose pregnancy test is positive; and,~8. those showing poor compliance with any aspect of the study;~9. foster children

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- DM1( 0.25 mg/kg /day) (Type: EXPERIMENTAL): Dextromethorphan 0.25 mg/kg per day
- DM2 (2.5 mg/kg/day) (Type: EXPERIMENTAL): Dextromethorphan 2.5 mg/kg/day
- DM3 (5mg/kg/day) (Type: EXPERIMENTAL): Dextromethorphan 5mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA GENERAL:~1. 12 years of age or older~2. Signed written informed consent~3. Willingness and ability to comply with schedule for follow-up visits~4. Contact lens removal prior to evaluation and treatment~5. Candidates must also have two of the following criteria:~   1. Presence of central or inferior steepening on the Pentacam or Orbscan map consistent with Keratoconus.~  2. Axial topography consistent with keratoconus.~  3. Steepest keratometry (Kmax) value of 47.00D~INCLUSION CRITERIA FOR ECTASIA:~History of having undergone a keratorefractive procedure and 2 of the following criteria:~1. Steepening by topography, either Pentacam or Orbscan~2. Thinning of cornea~3. Shift in the position of thinnest portion of cornea~4. Change in refraction with increasing myopia~5. Development of myopic astigmatism~6. Development of irregular astigmatism~7. Loss of BSCVA~   EXCLUSION CRITERIA:~   I. Eyes classified as either normal or atypical normal 2. Corneal pachymetry 350 microns at the thinnest point measured by Pentacam in the eye to be treated 3. A history of chemical injury or delayed epithelial healing in the eye to be treated.~   4. Pregnancy (including plan to become pregnant) or lactation during the course of the study 5. A known sensitivity to study medications 6. Patients with nystagmus or any other condition that would prevent a steady gaze during the treatment 7. Inability to cooperate with diagnostic tests. 8. Patients with a concomitant condition that, in the investigator's opinion, would interfere with or prolong epithelial healing.~   9. Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment.~   10. Patients who are unable to remain supine and tolerate a lid speculum for an extended period of time.~   -

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Riboflavin drops - epithelium on or off (Type: OTHER): Riboflavin is applied with Epithelium on or with it off. 6 months follow up to find out magnitude of Decrease in Kmax

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Male or female oncology patients who are enrolled in participating stomatogenic autologous or allogeneic PBSCT/BMT protocols, and are willing to participate in this study concurrently~ 2. Able to understand and sign protocol consent or assent~ 3. Age 16 years or older~EXCLUSION CRITERIA:~1. Pregnant or lactating females~2. Unable to follow oral rinsing directions~3. Intubation~4. Chronic use of medications confounding assessment of the inflammatory response (non-steroidal antiinflammatory drugs, antihistamines, and steroids- with the exception of decadron that is commonly used as an antiemetic in the PBSCT/BMT setting)~5. Pre-existing oral infection or upper respiratory infection that might maximize the possibility of an infection or sepsis contributing to a drug-related adverse event~6. Known hypersensitivity or allergic reaction to etanercept

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Main Study: Etanercept Mouthwash (Type: EXPERIMENTAL): Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
- Main Study: Placebo Mouthwash (Type: PLACEBO_COMPARATOR): Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.
- Pilot Study (Type: NO_INTERVENTION): Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility